Celldex Property Plant And Equipment Gross vs Total Current Liabilities Analysis
CLDX Stock | USD 39.94 0.23 0.57% |
Celldex Therapeutics financial indicator trend analysis is way more than just evaluating Celldex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Celldex Therapeutics is a good investment. Please check the relationship between Celldex Therapeutics Property Plant And Equipment Gross and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.
Property Plant And Equipment Gross vs Total Current Liabilities
Property Plant And Equipment Gross vs Total Current Liabilities Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Celldex Therapeutics Property Plant And Equipment Gross account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Celldex Therapeutics' Property Plant And Equipment Gross and Total Current Liabilities is 0.51. Overlapping area represents the amount of variation of Property Plant And Equipment Gross that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Celldex Therapeutics, assuming nothing else is changed. The correlation between historical values of Celldex Therapeutics' Property Plant And Equipment Gross and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant And Equipment Gross of Celldex Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Property Plant And Equipment Gross i.e., Celldex Therapeutics' Property Plant And Equipment Gross and Total Current Liabilities go up and down completely randomly.
Correlation Coefficient | 0.51 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Property Plant And Equipment Gross
Total Current Liabilities
Total Current Liabilities is an item on Celldex Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Celldex Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Celldex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.8 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.
2023 | 2024 (projected) | Extraordinary Items | 17.2M | 15.3M | Reconciled Depreciation | 2.9M | 3.1M |
Celldex Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Celldex Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Celldex Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 122.9M | 235.8M | 444.7M | 352.7M | 465.6M | 488.9M | |
Other Current Liab | 2.0M | 3.4M | 1.6M | 13.8M | 26.0M | 27.3M | |
Total Current Liabilities | 11.6M | 14.2M | 16.5M | 18.6M | 31.1M | 32.7M | |
Total Stockholder Equity | 94.0M | 209.4M | 419.5M | 326.2M | 429.2M | 450.6M | |
Property Plant And Equipment Net | 4.0M | 3.8M | 3.6M | 3.7M | 6.6M | 5.7M | |
Net Debt | (7.6M) | (40.4M) | (36.1M) | (25.4M) | (32.3M) | (33.9M) | |
Retained Earnings | (1.0B) | (1.1B) | (1.1B) | (1.3B) | (1.4B) | (1.3B) | |
Cash | 11.2M | 43.8M | 39.1M | 29.4M | 34.8M | 31.5M | |
Non Current Assets Total | 56.2M | 38.0M | 33.8M | 35.0M | 33.9M | 31.0M | |
Cash And Short Term Investments | 64.4M | 194.4M | 408.3M | 305.0M | 421.7M | 442.8M | |
Common Stock Shares Outstanding | 14.5M | 29.6M | 42.9M | 46.9M | 48.4M | 50.9M | |
Liabilities And Stockholders Equity | 122.9M | 235.8M | 444.7M | 352.7M | 465.6M | 488.9M | |
Non Current Liabilities Total | 17.3M | 12.3M | 8.7M | 7.9M | 5.3M | 5.1M | |
Other Current Assets | 2.3M | 3.4M | 2.6M | 12.7M | 5.5M | 2.9M | |
Other Stockholder Equity | 1.1B | 1.3B | 1.6B | 1.6B | 1.8B | 1.9B | |
Total Liab | 28.9M | 26.5M | 25.2M | 26.5M | 36.5M | 25.7M | |
Property Plant And Equipment Gross | 7.5M | 7.3M | 27.6M | 29.4M | 29.0M | 30.5M | |
Total Current Assets | 66.7M | 197.8M | 410.8M | 317.7M | 431.7M | 453.3M | |
Accumulated Other Comprehensive Income | 2.6M | 2.6M | 1.9M | 1.3M | 3.3M | 3.5M | |
Net Receivables | 1.0M | 1.8M | 172K | 347K | 4.5M | 4.8M | |
Inventory | (1.0M) | (1.8M) | (172K) | (347K) | 1.0 | 0.95 | |
Accounts Payable | 1.2M | 1.0M | 1.2M | 3.3M | 3.5M | 3.7M | |
Short Long Term Debt Total | 3.7M | 3.5M | 3.0M | 4.0M | 2.5M | 4.6M | |
Short Term Debt | 1.9M | 1.3M | 1.7M | 1.4M | 1.6M | 2.6M | |
Common Stock Total Equity | 12K | 17K | 40K | 47K | 54.1K | 65.1K | |
Common Stock | 12K | 17K | 40K | 47K | 56K | 64.5K | |
Intangible Assets | 52.2M | 34.2M | 30.3M | 31.3M | 27.2M | 34.2M | |
Current Deferred Revenue | 2.5M | 6.5M | 8.5M | 12M | 10.8M | 10.3M | |
Other Liab | 15.6M | 10.1M | 7.4M | 5.3M | 6.1M | 5.8M | |
Property Plant Equipment | 4.0M | 7.3M | 6.5M | 7.7M | 7.0M | 7.2M | |
Short Term Investments | 53.2M | 150.6M | 369.1M | 275.5M | 386.9M | 406.2M | |
Net Tangible Assets | 45.3M | 178.7M | 392.3M | 299.0M | 343.9M | 361.1M | |
Retained Earnings Total Equity | (962.4M) | (1.0B) | (1.1B) | (1.1B) | (1.0B) | (1.1B) | |
Capital Surpluse | 1.1B | 1.1B | 1.3B | 1.6B | 1.8B | 1.0B | |
Non Current Liabilities Other | 17.3M | 10.1M | 7.4M | 5.3M | 4.4M | 4.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.Note that the Celldex Therapeutics information on this page should be used as a complementary analysis to other Celldex Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Complementary Tools for Celldex Stock analysis
When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
Is Celldex Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Celldex Therapeutics. If investors know Celldex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Celldex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.86) | Revenue Per Share 0.118 | Quarterly Revenue Growth (0.84) | Return On Assets (0.16) | Return On Equity (0.25) |
The market value of Celldex Therapeutics is measured differently than its book value, which is the value of Celldex that is recorded on the company's balance sheet. Investors also form their own opinion of Celldex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Celldex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Celldex Therapeutics' market value can be influenced by many factors that don't directly affect Celldex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Celldex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Celldex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Celldex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.